Amicus’ Pompe disease therapy joins early access scheme

Patients with late-stage Pompe disease who are failing to respond to enzyme replacement therapy will now have early access to an alternative treatment option, after Amicus Therapeutics’  cipaglucosidase alfa with miglustat was approved for the UK’s Early Access to Medicine Scheme (EAMS).